JNJ-37822681 dihydrochloride

Research use only, not for human use.

JNJ-37822681 dihydrochloride is a novel, highly selective dopamine D? receptor antagonist characterized by a rapid dissociation rate from the dopamine D? receptor.

JNJ-37822681 dihydrochloride is a novel, highly selective dopamine D? receptor antagonist characterized by a rapid dissociation rate from the dopamine D? receptor. JNJ-37822681 dihydrochloride shows a moderate binding affinity for the dopamine D2L receptor with a Ki of 158 nM.(In Vivo):JNJ-37822681 dihydrochloride occupied D2 receptors in rat brain at relatively low doses (ED50 = 0.39 mg/kg) and was effective in animal models of psychosis (e.g., inhibition of apomorphine-induced stereotypy or D-amphetamine/phencyclidine-induced hyperlocomotion).

——

JNJ-37822681 (0.0025-40 mg/kg; i.h.; once) blocks D2 receptors in rat brain at relatively low doses with an ED50 value of 0.39 mg/kg and has effective in animal models of psychosis.JNJ-37822681 (0.01-2.5 mg/kg; i.h.; once) induces minimal prolactin release at the lowest doses required for central D2 receptor blockade. Animal Model:Female Sprague-Dawley rats with apomorphine-induced, d-amphetamine-induced, or phencyclidine-induced Dosage:0.0025-40 mg/kg Administration:Subcutaneous injection; onceResult:Inhibited of D-amphetamine-induced hyperlocomotion with an ED50 value of 1.0 mg/kg.Inhibited of apomorphine-induced stereotypy with an ED50 value of 0.19 mg/kg.Inhibited of phencyclidine-induced hyperlocomotion with an ED50 value of 4.7 mg/kg.Animal Model:Female Sprague-Dawley rats Dosage:0.01, 0.02, 0.04, 0.08, 0.16, 0.31, 0.63, 1.25, and 2.5 mg/kg Administration:Subcutaneous injection; onceResult:Increased prolactin release in a dose-dependent manner.

——

GPCR/G Protein

Dopamine Receptor

HBV

——

——

2108806-02-4

445.26

C17H19Cl2F5N4

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (74.86 mM)

Cl.Cl.Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F

——

(-20℃)

With Ice Pack

≥ 2 years